Global health news is largely good

By ACSH Staff — Dec 14, 2012
The Global Burden of Disease Study 2010 the largest systematic effort to quantify world health levels and trends has released its comprehensive review of life expectancy and global health threats.

The Global Burden of Disease Study 2010 the largest systematic effort to quantify world health levels and trends has released its comprehensive review of life expectancy and global health threats.

Chantix risks may outweigh its benefits

By ACSH Staff — Dec 14, 2012
Speaking of smoking, users of the smoking-cessation drug Chantix may be at higher risk for cardiovascular problems, the U.S. Food and Drug Administration stated Wednesday. A meta-analysis of clinical trials that compared patients who took Chantix to patients who took a placebo found that those on Chantix had a higher occurrence of major adverse cardiovascular events including death, MI, and stroke.

Speaking of smoking, users of the smoking-cessation drug Chantix may be at higher risk for cardiovascular problems, the U.S. Food and Drug Administration stated Wednesday.
A meta-analysis of clinical trials that compared patients who took Chantix to patients who took a placebo found that those on Chantix had a higher occurrence of major adverse cardiovascular events including death, MI, and stroke.

No good reason to prolong Herceptin therapy

By ACSH Staff — Dec 14, 2012
A year of maintenance therapy with Herceptin remains the standard of care for patients with HER2-positive breast cancer, researchers reported at the San Antonio Breast Cancer Symposium. The new phase 3 trial involved more than 5,000 women from several countries. After completing initial treatment for their early stage HER2-positive breast cancer, the women were randomly assigned to received Herceptin every three weeks for one year, two years or not at all.

A year of maintenance therapy with Herceptin remains the standard of care for patients with HER2-positive breast cancer, researchers reported at the San Antonio Breast Cancer Symposium.
The new phase 3 trial involved more than 5,000 women from several countries. After completing initial treatment for their early stage HER2-positive breast cancer, the women were randomly assigned to received Herceptin every three weeks for one year, two years or not at all.

Organic pesticides: Ask someone who knows

By ACSH Staff — Dec 14, 2012
As you may recall, yesterday s Dispatch covered a distorted, alarmist story on the harms of pesticides. Will Westerling, a licensed Pest Control Advisor in the State of California, wrote in with his views.

As you may recall, yesterday s Dispatch covered a distorted, alarmist story on the harms of pesticides.
Will Westerling, a licensed Pest Control Advisor in the State of California, wrote in with his views.

An aspirin a day to keep the doctor away

By ACSH Staff — Dec 13, 2012
As America s health care spending continues to grow, does it become the government s responsibility to use public health policy to campaign for and encourage practical actions officials believe we Americans should be taking to rein in healthcare costs? David B.

As America s health care spending continues to grow, does it become the government s responsibility to use public health policy to campaign for and encourage practical actions officials believe we Americans should be taking to rein in healthcare costs? David B.

The pesticide and cosmetic pests are back

By ACSH Staff — Dec 13, 2012
As the year comes to an end, the scares keep coming, today as often before in the form of pesticides and cosmetics. These alarmist stories are simply baseless and raise needless consumer concerns based only on the precautionary principle.

As the year comes to an end, the scares keep coming, today as often before in the form of pesticides and cosmetics. These alarmist stories are simply baseless and raise needless consumer concerns based only on the precautionary principle.

Diabetes-related vision loss on the rise

By ACSH Staff — Dec 13, 2012
Nonrefractive vision loss, caused by conditions including diabetic retinopathy and macular degeneration, is a type of vision loss that cannot be corrected with glasses. Studies have shown this problem to be on the rise in people under 40, as has the prevalence of diabetes. Could the two be connected?

Nonrefractive vision loss, caused by conditions including diabetic retinopathy and macular degeneration, is a type of vision loss that cannot be corrected with glasses. Studies have shown this problem to be on the rise in people under 40, as has the prevalence of diabetes. Could the two be connected?

Coffee: The wonder drug?

By ACSH Staff — Dec 13, 2012
We have yet another candidate for the silliest scientific study of the year, although it will probably just win for this week. A new study, published in the American Journal of Epidemiology, claims that heavy coffee drinkers those who drink more than four cups of regular (caffeinated) coffee a day may cut their risk of dying from cancers of the mouth and throat by nearly half.

We have yet another candidate for the silliest scientific study of the year, although it will probably just win for this week. A new study, published in the American Journal of Epidemiology, claims that heavy coffee drinkers those who drink more than four cups of regular (caffeinated) coffee a day may cut their risk of dying from cancers of the mouth and throat by nearly half.

Smoking and sudden death even worse than you thought

By ACSH Staff — Dec 12, 2012
A new analysis of the Nurse s Health Study has quantified just how much smoking contributes to sudden cardiac death and how quitting can potentially reduce or eliminate that risk.

A new analysis of the Nurse s Health Study has quantified just how much smoking contributes to sudden cardiac death and how quitting can potentially reduce or eliminate that risk.